) recently announced encouraging top-line data from a phase III
study, FIXTURE (the Full year Investigative eXamination of
secukinumab vs. eTanercept Using 2 dosing Regimens to determine
Efficacy in psoriasis), on psoriasis candidate, secukinumab
In the randomized, double-blind, placebo-controlled study (n
=1,307), secukinumab was evaluated for efficacy in patients
suffering from moderate-to-severe plaque psoriasis. It was
observed in the study that secukinumab was more effective in
clearing skin than
The study met primary as well as secondary endpoints. The
safety profile of secukinumab was consistent with previously
reported results from phase II studies in moderate-to-severe
Secukinumab is one of the most promising pipeline candidates
at Novartis - we are encouraged by the results and look forward
to detailed results that will be presented later this year.
Novartis also remains on track to file for approval this
We note that secukinumab is also being evaluated for other
indications like psoriatic arthritis, ankylosing spondylitis and
rheumatoid arthritis among others. The phase III studies for
these indications are ongoing with results expected in 2014.
Additionally, secukinumab is in phase II studies for the
treatment of multiple sclerosis.
Secukinumab is the first anti IL-17A on which phase III
results have been presented. We note that Amgen has an anti IL-17
candidate, brodalumab, in its pipeline. Brodalumab is currently
in phase III studies for the psoriasis indication.
Meanwhile, currently approved products include
) Humira among others.
Novartis currently carries a Zacks Rank #3 (Hold). Right now,
) looks well placed with a Zacks Rank #1 (Strong Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis
VALEANT PHARMA (VRX): Free Stock Analysis
To read this article on Zacks.com click here.